What is ComboCap?
ComboCap Health represents a paradigm shift in pharmaceutical delivery, specializing in the world's first side-by-side, dual-chamber, wet-and-dry combination capsule. Founded by Jacques van Rooyen, the company has successfully navigated seven years of rigorous R&D to secure a robust international patent portfolio covering design, machinery, and manufacturing processes across North America, the EU, Asia, and Australia. By enabling the co-administration of incompatible substances within a single delivery vehicle, ComboCap provides pharmaceutical and nutraceutical manufacturers with a novel platform for combination therapies that were previously technically unfeasible. The company's operational core in New Jersey serves as the nexus for its global manufacturing rights, ensuring strict quality control and scalability for its proprietary membrane-based technology.
How much funding has ComboCap raised?
ComboCap has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in ComboCap
PPP
Public-Private Partnership
What's next for ComboCap?
Looking ahead, ComboCap is poised to capitalize on the increasing demand for complex drug delivery systems that improve patient compliance and therapeutic efficacy. The current late-stage funding trajectory suggests a focus on aggressive market penetration and the scaling of manufacturing throughput to meet international demand. Strategic priorities likely include the expansion of licensing agreements with major pharmaceutical partners and the further refinement of its automated production lines to maintain its competitive moat. As the company continues to leverage its intellectual property, it is well-positioned to define the standard for next-generation combination therapies, potentially attracting further institutional interest as it scales its global supply chain and operational capacity.
See full ComboCap company page
